Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy.
about
CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer.CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells.Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α.Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinomaTrial Watch: Therapeutic vaccines in metastatic renal cell carcinomaLenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft modelA phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma.5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.Update on vaccine development for renal cell cancer.Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.Vaccine therapy for renal cancer.Naptumomab estafenatox: a new immunoconjugate.5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.Dendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials.Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4.A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer.Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.The current status of immunobased therapies for metastatic renal-cell carcinoma.Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft models.
P2860
Q33268298-09D87F5A-7996-4C84-B94F-7BEB7C084C42Q33550832-942A8BB2-5C7B-44E8-8F3D-B6A1E4994587Q34260594-812267AE-EE16-4671-84E8-F0B3C4967C34Q35552042-E33A2BFB-4B0F-4CC4-8569-9D968B3A242CQ35677962-03EAF923-E50D-48EF-A858-A14553A3E94CQ35799377-69B2AB34-C28F-456C-9055-B8F031CBD621Q35844148-5F3BC3AB-F27E-45E5-8715-C995A711890BQ36177214-18F99626-B1BD-459A-AA23-60715D406739Q36609877-DBB76A13-B9A5-45A2-B683-3ACCE84E523BQ36922276-F80CEF4B-4CCB-40CF-B9F4-DBFAB433D4A6Q36989720-68AC6A79-6485-4008-AC0C-D9CFF69C4460Q37074226-84D36B26-199B-4173-8EA9-89B8D7744C97Q37259586-9106BA68-0A36-4C9A-ACB7-3E14AA63E02CQ37669341-543599CE-7859-4B90-B898-8D58571D214CQ37678414-2BB5E0AD-F9FC-423A-9F91-7D8BF1649C5EQ37725613-463766EE-CF89-46A0-92BC-4A8995BF96DAQ38059516-89E90AE4-FE88-4DF4-B2F4-241E706FE12EQ38123176-0CD3E7AB-A0C9-4FC1-A030-DA94AB505A1CQ38373731-B566C5BA-CD86-4C76-8D9E-0D66080FDF41Q38984929-2742B0DF-7319-4A7B-9569-FB13446482D2Q40357390-39EBA6A4-9F88-4621-A50F-78F7DE686203Q45025116-FE3AF9F9-324B-42C2-900A-D935413303B3Q47097756-E2D56150-0DB6-4A43-BAD7-FFE243DD721CQ49843670-9D954CA2-B037-4F31-8140-CCC531116D60Q53686359-4D6587D8-A222-449A-9C9C-5FC57CAE6513
P2860
Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Expression of the 5T4 oncofoet ...... or T-cell-based immunotherapy.
@ast
Expression of the 5T4 oncofoet ...... or T-cell-based immunotherapy.
@en
type
label
Expression of the 5T4 oncofoet ...... or T-cell-based immunotherapy.
@ast
Expression of the 5T4 oncofoet ...... or T-cell-based immunotherapy.
@en
prefLabel
Expression of the 5T4 oncofoet ...... or T-cell-based immunotherapy.
@ast
Expression of the 5T4 oncofoet ...... or T-cell-based immunotherapy.
@en
P2093
P2860
P356
P1476
Expression of the 5T4 oncofoet ...... or T-cell-based immunotherapy.
@en
P2093
D E Gilham
N W Clarke
R E Hawkins
R W Griffiths
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602776
P407
P577
2005-09-01T00:00:00Z
P5875
P6179
1009647920